Effect of Omalizumab Therapy on Coagulation Parameters and Total Immunoglobulin E Levels in Patients with Chronic Idiopathic Urticaria and Bullous Pemphigoid
| Autor: | Güneş Gür Aksoy, Yıldız Hayran, Pınar Uysal, Ayşe Öktem, Başak Yalçin, Ahmet Uğur Atilan, Neslihan Akdogan |
|---|---|
| Jazyk: | turečtina |
| Rok vydání: | 2018 |
| Předmět: |
bullous pemphigoid
medicine.medical_specialty Anti-immunoglobulin E therapy business.industry Total immunoglobulin Dermatology Omalizumab lcsh:RL1-803 medicine.disease chronic urticaria immunoglobulin E Coagulation coagulation parameters lcsh:Dermatology Medicine omalizumab In patient Chronic idiopathic urticaria Bullous pemphigoid business medicine.drug |
| Zdroj: | Turk Dermatoloji Dergisi, Vol 12, Iss 4, Pp 159-166 (2018) |
| ISSN: | 1308-5255 1307-7635 |
| Popis: | Objective:The aim of this study is to assess the impact of omalizumab on coagulation biomarkers and immunoglobulin E (IgE) levels in chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) and bullous pemphigoid (BP) patients.Methods:Medical records of 31 CIU/CSU and 16 BP patients were reviewed according to the inclusion and exclusion criteria. Laboratory parameters for coagulation status and IgE levels at baseline and in the first 12-week period of omalizumab therapy were retrieved and analysed in the light of clinical response to the treatment.Results:At baseline, in CIU/CSU patients, IgE levels were significantly higher in responders [184.5 IU/mL (62-307 IU/mL)] than non-responders [25.6 IU/mL (10.8-30.2 IU/mL)] (p=0.021). During the first 12 weeks of omalizumab therapy, a dramatic decrease in D-dimer levels was observed in serial measurements of CIU/CSU (p=0.001) and also BP patients (p=0.017). Total IgE levels were increased after omalizumab usage in all study groups (p=0.003) and elevation of IgE levels was found significant for CIU/CSU but not for BP (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|